[20] The MHRA will be responsible for evaluating any future marketing authorisation application for retatrutide across the UK
Safety data confirm that GLP-1RAs and TZP increase the risk of gastrointestinal adverse events (mostly mild-to-moderate), including nausea, diarrhea, and vomiting that are usually well-tolerated and resolved in a few weeks of treatment because of tachyphylaxis (especially with long-acting analogues and TZP)
This data point matters because it suggests that while some immune response is possible, the clinical impact remains negligible for most users
If this site is slow for you, then your routing may be messed up, and this issue does not only affect done.land , but potentially a few other websites and downloads as well
Setting weight loss as the standard for success does not address other potential measures of success, such as improved metabolic markers (blood sugar, cholesterol), lifestyle, mental health, and activities of daily living